Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nitric BioTherapeutics has initiated a Phase II clinical trial for the treatment of chronic wounds using nitric oxide.
Subscribe to our email newsletter
When delivered topically to the wound, nitric oxide gas (gNO) has a number of known activities believed to be beneficial in the healing of wounds, including antimicrobial and anti-inflammatory action, regulation of collagen formation, and an ability to increase blood flow. gNO has been used to treat chronic wound patients in Canada under a Compassionate Care program.
Frank McCaney, CEO of Nitric Bio, said: “We are optimistic about nitric oxide’s potential to help heal chronic wounds, which have become a burgeoning health care problem fueled by the increased prevalence of diabetes and obesity.”